Press release
Fragile X Syndrome Market Expected to Experience Major Growth by 2032, According to DelveInsight | Novartis, Neuren Pharma, Roche, Seaside Therapeutics, Inc., Marinus Pharma, Lysogene
DelveInsight's "Fragile X Syndrome Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Fragile X Syndrome, historical and forecasted epidemiology as well as the Fragile X Syndrome market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.To Know in detail about the Fragile X Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Fragile X Syndrome Market Forecast
https://www.delveinsight.com/sample-request/fragile-x-syndrome-fxs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key facts of the Fragile X Syndrome Market Report:
• The Fragile X Syndrome market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• In 2023, the collective diagnosed prevalent cases of Fragile X Syndrome (FXS) across the seven major markets (7MM) were estimated to be approximately 123,000. Specifically, within the United States, there were approximately 71,000 diagnosed prevalent cases of FXS.
• In 2023, within the United States, approximately 60% of the prevalent cases of Fragile X Syndrome were reported in males, while nearly 40% were identified in females.
• Key Fragile X Syndrome Companies: Zynerba Pharmaceuticals, Confluence Pharmaceuticals, Tetra Therapeutics, Neuren Pharmaceuticals, Healx, Craig Erickson, Zynerba Pharmaceuticals, Nova Mentis Life Science, and others
• Key Fragile X Syndrome Therapies: Zygel, Acamprosate, BPN14770, Trofinetide, Sulindac (HLX-0201), Gaboxadol, ZYN002, Psilocybin, and others
• The Fragile X Syndrome epidemiology based on gender analyzed that males are affected more as compared to females, in the case of Fragile X Syndrome (FXS)
• The Fragile X Syndrome market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Fragile X Syndrome pipeline products will significantly revolutionize the Fragile X Syndrome market dynamics.
Fragile X Syndrome Overview
Fragile X Syndrome is a genetic condition characterized by intellectual disability, behavioral and learning challenges, and various physical features. It is caused by a mutation in the FMR1 gene located on the X chromosome. This mutation leads to a reduction or absence of the FMR1 protein, which is essential for normal brain development. Fragile X Syndrome is the most common inherited cause of intellectual disability, affecting males more severely than females.
Get a Free sample for the Fragile X Syndrome Market Report:
https://www.delveinsight.com/report-store/fragile-x-syndrome-fxs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Fragile X Syndrome Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Fragile X Syndrome Epidemiology Segmentation:
The Fragile X Syndrome market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of Fragile X Syndrome
• Prevalent Cases of Fragile X Syndrome by severity
• Gender-specific Prevalence of Fragile X Syndrome
• Diagnosed Cases of Episodic and Chronic Fragile X Syndrome
Download the report to understand which factors are driving Fragile X Syndrome epidemiology trends @ Fragile X Syndrome Epidemiology Forecast
https://www.delveinsight.com/sample-request/fragile-x-syndrome-fxs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Fragile X Syndrome Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Fragile X Syndrome market or expected to get launched during the study period. The analysis covers Fragile X Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Fragile X Syndrome Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Fragile X Syndrome Therapies and Key Companies
• Zygel: Zynerba Pharmaceuticals
• Acamprosate: Confluence Pharmaceuticals
• BPN14770: Tetra Therapeutics
• Trofinetide: Neuren Pharmaceuticals
• Sulindac (HLX-0201): Healx
• Gaboxadol: Craig Erickson
• ZYN002: Zynerba Pharmaceuticals
• Psilocybin: Nova Mentis Life Science
Discover more about therapies set to grab major Fragile X Syndrome market share @ Fragile X Syndrome Treatment Market
https://www.delveinsight.com/sample-request/fragile-x-syndrome-fxs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Fragile X Syndrome Market Strengths
• Growing Research and development are increasing the demand for FXS treatment.
• Advances in DNA technology, including CRISPRCas9, have been used to correct the expanded CGG repeat in induced pluripotent stem cells. Eventually, it might be possible to add these corrected stem cells into the central nervous systems of those with FXS
Fragile X Syndrome Market Opportunities
• The rise in the prevalence of FXS stimulates the research and development of the drug, as it is likely to provide an appropriate environment for newer products to be profitable.
• Increasing population gives a lucrative opportunity to increase the awareness and innovation of therapeutics to drive FXS market.
Scope of the Fragile X Syndrome Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Fragile X Syndrome Companies: Zynerba Pharmaceuticals, Confluence Pharmaceuticals, Tetra Therapeutics, Neuren Pharmaceuticals, Healx, Craig Erickson, Zynerba Pharmaceuticals, Nova Mentis Life Science, and others
• Key Fragile X Syndrome Therapies: Zygel, Acamprosate, BPN14770, Trofinetide, Sulindac (HLX-0201), Gaboxadol, ZYN002, Psilocybin, and others
• Fragile X Syndrome Therapeutic Assessment: Fragile X Syndrome current marketed and Fragile X Syndrome emerging therapies
• Fragile X Syndrome Market Dynamics: Fragile X Syndrome market drivers and Fragile X Syndrome market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Fragile X Syndrome Unmet Needs, KOL's views, Analyst's views, Fragile X Syndrome Market Access and Reimbursement
To know more about Fragile X Syndrome companies working in the treatment market, visit @ Fragile X Syndrome Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/fragile-x-syndrome-fxs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Table of Contents
1. Fragile X Syndrome Market Report Introduction
2. Executive Summary for Fragile X Syndrome
3. SWOT analysis of Fragile X Syndrome
4. Fragile X Syndrome Patient Share (%) Overview at a Glance
5. Fragile X Syndrome Market Overview at a Glance
6. Fragile X Syndrome Disease Background and Overview
7. Fragile X Syndrome Epidemiology and Patient Population
8. Country-Specific Patient Population of Fragile X Syndrome
9. Fragile X Syndrome Current Treatment and Medical Practices
10. Fragile X Syndrome Unmet Needs
11. Fragile X Syndrome Emerging Therapies
12. Fragile X Syndrome Market Outlook
13. Country-Wise Fragile X Syndrome Market Analysis (2019-2032)
14. Fragile X Syndrome Market Access and Reimbursement of Therapies
15. Fragile X Syndrome Market Drivers
16. Fragile X Syndrome Market Barriers
17. Fragile X Syndrome Appendix
18. Fragile X Syndrome Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Related Reports:
Fragile X Syndrome Epidemiology https://www.delveinsight.com/report-store/fragile-x-syndrome-fxs-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Fragile X Syndrome Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Fragile X Syndrome epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports by DelveInsight
Point Of Care Glucose Testing Market
https://www.delveinsight.com/report-store/point-of-care-glucose-testing-market
DelveInsight's 'Point of Care Glucose Testing - Market Insight, Competitive Landscape and Market Forecast, 2030' report delivers an in-depth understanding of Point of Care Glucose Testing and the historical and forecasted Point of Care Glucose Testing market trends, globally, which comprises of North America, Europe, APAC, and RoW.
Substance Drug Abuse Market
https://www.delveinsight.com/report-store/substance-drug-abuse-market
DelveInsight's "Substance Drug Abuse Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Substance (Drug) Abuse, historical and forecasted epidemiology as well as the Substance (Drug) Abuse market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Tongue Cancer Market
https://www.delveinsight.com/report-store/tongue-cancer-market
DelveInsight's "Tongue Cancer Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Tongue Cancer, historical and forecasted epidemiology as well as the Tongue Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Trastuzuma Biosimilar
https://www.delveinsight.com/report-store/trastuzumab-biosimilars-insight
DelveInsight's, "Trastuzumab Biosimilar Insight, 2024" report provides comprehensive insights about 35+ companies and 35+ marketed and pipeline drugs in Trastuzumab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Fragile X Syndrome Market Expected to Experience Major Growth by 2032, According to DelveInsight | Novartis, Neuren Pharma, Roche, Seaside Therapeutics, Inc., Marinus Pharma, Lysogene here
News-ID: 3644176 • Views: …
More Releases from DelveIinsight Business Research

Advanced Renal Cell Carcinoma Market Report 2034: Epidemiology Data, Therapies, …
DelveInsight's "Advanced Renal Cell Carcinoma Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Antibody Drug Conjugates, historical and forecasted epidemiology as well as the Antibody Drug Conjugates market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Advanced Renal Cell Carcinoma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Advanced Renal…

PCSK9 Inhibitors Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, PCSK9 Inhibitors pipeline constitutes 14+ key companies continuously working towards developing 14+ PCSK9 Inhibitors treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"PCSK9 Inhibitors Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the PCSK9 Inhibitors Market.
The PCSK9…

Metastatic Prostate Cancer Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clin …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Metastatic Prostate Cancer pipeline constitutes 75+ key companies continuously working towards developing 75+ Metastatic Prostate Cancer treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Metastatic Prostate Cancer Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Metastatic Prostate…

Bunion (Hallux Valgus) Market to Expand Significantly by 2034, States DelveInsig …
DelveInsight's "Bunion Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Bunion, historical and forecasted epidemiology as well as the Bunion market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Bunion market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Bunion Market Forecast
https://www.delveinsight.com/sample-request/hallux-valgus-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key facts of the Bunion…
More Releases for Fragile
Fragile X Syndrome Fxs Treatment Market Size, Share & Trends [2035]
The Fragile X Syndrome Market Is Set To Grow At An Estimated CAGR Of 8.4% From 2025 To 2034, Rising From $1.2 Billion In 2024 To $2.6 Billion By 2034.
On April 15, 2025, Exactitude Consultancy., Ltd. released a research report offers a comprehensive examination of the various processes and materials used in the production of Fragile X Syndrome Fxs Treatment market goods. The market study excludes key regions that are…
Fragile X-Syndrome Therapeutics Market: Treatment Strategies and Emerging Therap …
The Summary of the Fragile X-Syndrome Market Report
The MMR offers a concise depiction of the "Fragile X-Syndrome Market" industry, delivering an in-depth analysis of the Fragile X-Syndrome market. It emphasizes standard subjects while tailoring data to suit specific requirements. This overview serves as a comprehensive guide for investors seeking insights into the current landscape of the Fragile X-Syndrome industry.
Fragile X-Syndrome Market Expansion
Fragile X-Syndrome Market size is expected to grow at…
Sparkling Wine market status most fragile speculative growth trends
A new statistical surveying study titled Sparkling Wine Market investigates a few critical features identified with Sparkling Wine Market covering industry condition, division examination, and focused scene. Down to earth ideas of the market are referenced in a straightforward and unassuming way in this report. A far-reaching and exhaustive essential investigation report features various actualities, for example, improvement factors, business upgrade systems, measurable development, monetary benefit or misfortune to support…
IT Education and Training MARKET STATUS – MOST FRAGILE & SPECULATIVE GROWTH TR …
” The newly added research report illustrating details on global IT Education and Training market delivers key insights on specific market elements such as competition intensity, regional growth opportunities, vendor profiles and requisite understanding of most potential growth triggers and vendor activities that harbinger growth in global IT Education and Training market. Crucial details on SWOT analysis, PESTEL analysis and Porter’s Five Forces analytical reviews have been professed with great…
Life Sciences Software market status most fragile speculative growth trends
Detailed research added by Ample Market Research offering a comprehensive analysis of the developments, growth outlook, driving factors, and key players of the Life Sciences Software market in the latest research report. The research study concisely dissects the Life Sciences Software and unearths valuable estimations pertaining to the profit projections, market size, sales capacity, and numerous other crucial parameters. Also, the Life Sciences Software Market report appraises the industry fragments…
Fragile X Syndrome-Pipeline Review H2 2018
Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Fragile X Syndrome-Pipeline Review, H2 2018, provides an overview of the Fragile X Syndrome (Genetic Disorders) pipeline landscape.
Fragile X syndrome is a genetic condition that causes a range of developmental problems including learning disabilities and cognitive impairment. Fragile X syndrome is caused by a change in a gene called FMR1. Fragile X syndrome occurs both in male and female. Symptoms include delay…